MedTrace Logo

Observational Study to Evaluate the Safety While Using Levemir®

NCT00701155 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3593

Last updated 2023-11-02

No results posted yet for this study

Summary

This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using insulin Levemir® under normal clinical practice conditions in Egypt.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

DRUG

insulin detemir

Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701155 on ClinicalTrials.gov